COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
08
07
2022
accepted:
25
10
2022
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19. Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression. Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status. 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.
Sections du résumé
Background
UNASSIGNED
Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19.
Methods
UNASSIGNED
Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression.
Findings
UNASSIGNED
Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status.
Conclusion
UNASSIGNED
1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.
Identifiants
pubmed: 36960350
doi: 10.1183/23120541.00317-2022
pii: 00317-2022
pmc: PMC10030059
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: P. Tymoszuk owns the Data Analytics as a Service data science enterprise and is (from May 2021 on) a freelance data scientist working in his own enterprise; he received honoraria for the statistical analysis of the CovILD study. All other authors have no conflict of interest related to this study to declare.
Références
Lancet Respir Med. 2021 Jan;9(1):107-116
pubmed: 33217366
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34244323
Radiology. 2022 Aug;304(2):462-470
pubmed: 35348379
Radiology. 2021 Oct;301(1):E353-E360
pubmed: 34032513
Elife. 2022 Feb 08;11:
pubmed: 35131031
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Psychosom Med. 2016 Jan;78(1):5-12
pubmed: 26461855
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Psychosom Res. 1998 Nov;45(5):411-7
pubmed: 9835234
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
Lancet. 2021 Feb 6;397(10273):455-457
pubmed: 33357467
Health Qual Life Outcomes. 2021 Mar 6;19(1):76
pubmed: 33676523
Open Forum Infect Dis. 2021 Jul 16;8(8):ofab384
pubmed: 34386546
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Thromb Haemost. 2021 Oct;19(10):2546-2553
pubmed: 34375505
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
ESC Heart Fail. 2021 Jun;8(3):2232-2239
pubmed: 33773099
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Stat Softw. 2017 Aug;79:
pubmed: 30686944
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Radiology. 2022 Mar;302(3):709-719
pubmed: 34609153
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
Sci Rep. 2021 Nov 22;11(1):22666
pubmed: 34811387
Respir Care. 2018 Jan;63(1):77-85
pubmed: 28874609
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Assessment. 2004 Mar;11(1):94-101
pubmed: 14994958
ERJ Open Res. 2022 Apr 11;8(2):
pubmed: 35415186